<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488448</url>
  </required_header>
  <id_info>
    <org_study_id>11-09-329</org_study_id>
    <nct_id>NCT01488448</nct_id>
  </id_info>
  <brief_title>A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis</brief_title>
  <official_title>A Double-Blind, Controlled, Randomized Clinical Trial of Nebulized Hypertonic Saline for Hospitalized Infants With Viral Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if nebulized hypertonic saline (or extra salty
      water mist) helps infants less than 12 months old hospitalized with bronchiolitis (or bad
      chest colds) get better enough to be discharged from the hospital sooner than those infants
      given nebulized normal saline (or regular salty water mist).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiolitis is a common admitting diagnosis for children less than 1 year of age. Although
      bronchiolitis has a high prevalence, there is a lack of a unified inpatient treatment plan
      beyond supportive care of supplemental oxygen and intravenous hydration. There have been many
      different approaches to the treatment of bronchiolitis, but none have conclusively proven to
      be beneficial. Several early studies show promise for the use of nebulized hypertonic saline,
      however the majority of these studies are done outside the United States and with adjunctive
      therapy. To date, the data suggesting that nebulized hypertonic saline is safe and effective
      for reducing length of stay in bronchiolitis is strong but not generalizable for the United
      States. The objective of this study is to conduct the first double-blind, randomized
      controlled trial in the United States of nebulized hypertonic saline without adjunctive
      therapy, including infants with bronchiolitis, including those with prior history of wheeze,
      to assess the effect on length of stay and therefore resource utilization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Stay in the Study-LOS--Intention to Treat Analysis</measure>
    <time_frame>Time of first study treatment until time of discharge</time_frame>
    <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay in the Study-LOS by Per Protocol Analysis</measure>
    <time_frame>Time of first study treatment until time of discharge</time_frame>
    <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission for Bronchiolitis Within 7 Days of Discharge</measure>
    <time_frame>within 7 days of hospital discharge</time_frame>
    <description>Phone call at 7 days to assess for readmission to any hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Worsening</measure>
    <time_frame>though hospitalization/time period receiving study treatment, average 2-3 days</time_frame>
    <description>transfer to the Pediatric Intensive Care Unit (PICU) (including withdrawn from the study for bronchodilator administration who were then transferred to the PICU), or Respiratory Distress Assessment Instrument (RDAI) increase of 4 or more points within 30 minutes of a study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Adverse Events</measure>
    <time_frame>Time of enrollment in the study through 1 week after hospital discharge</time_frame>
    <description>Clinical worsening events (defined prior) + 7 day readmissions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Nebulized Hypertonic Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mL nebulized 3% sodium chloride every 4 hours until discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulized Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% sodium chloride</intervention_name>
    <description>4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge</description>
    <arm_group_label>Nebulized Hypertonic Saline</arm_group_label>
    <other_name>hypertonic saline</other_name>
    <other_name>HS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge</description>
    <arm_group_label>Nebulized Normal Saline</arm_group_label>
    <other_name>normal saline</other_name>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 0-12 months of age admitted to the hospital with a diagnosis of
             bronchiolitis.

        Exclusion Criteria:

          -  status asthmaticus

          -  chronic cardiopulmonary disease

          -  Trisomy 21

          -  immunodeficiency or transplant recipient

          -  neuromuscular disease

          -  admission directly to the intensive care unit

          -  previous use of nebulized hypertonic saline less than 12 hours prior to presentation

          -  previous enrollment in the study in the 72 hours prior to presentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alyssa H Silver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>August 7, 2014</results_first_submitted>
  <results_first_submitted_qc>August 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Alyssa Silver</investigator_full_name>
    <investigator_title>Attending Physician, Pediatric Hospitalist, Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Hypertonic saline</keyword>
  <keyword>Bronchiolitis</keyword>
  <keyword>Infants</keyword>
  <keyword>Wheezing</keyword>
  <keyword>Nebulized</keyword>
  <keyword>Bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic Saline</title>
          <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline</title>
          <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.86" spread="3.01"/>
                    <measurement group_id="B2" value="4.39" spread="2.95"/>
                    <measurement group_id="B3" value="4.1" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay in the Study-LOS--Intention to Treat Analysis</title>
        <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
        <time_frame>Time of first study treatment until time of discharge</time_frame>
        <population>Intention to Treat Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in the Study-LOS--Intention to Treat Analysis</title>
          <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
          <population>Intention to Treat Analysis</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.2" upper_limit="4.6"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.2" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission for Bronchiolitis Within 7 Days of Discharge</title>
        <description>Phone call at 7 days to assess for readmission to any hospital</description>
        <time_frame>within 7 days of hospital discharge</time_frame>
        <population>This population is those who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebulized Hypertonic Saline</title>
            <description>4mL nebulized 3% sodium chloride every 4 hours until discharge
3% sodium chloride: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Nebulized Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
0.9% sodium chloride: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission for Bronchiolitis Within 7 Days of Discharge</title>
          <description>Phone call at 7 days to assess for readmission to any hospital</description>
          <population>This population is those who completed the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Worsening</title>
        <description>transfer to the Pediatric Intensive Care Unit (PICU) (including withdrawn from the study for bronchodilator administration who were then transferred to the PICU), or Respiratory Distress Assessment Instrument (RDAI) increase of 4 or more points within 30 minutes of a study treatment</description>
        <time_frame>though hospitalization/time period receiving study treatment, average 2-3 days</time_frame>
        <population>all patients enrolled in the study were analyzed for events related to clinical worsening</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Worsening</title>
          <description>transfer to the Pediatric Intensive Care Unit (PICU) (including withdrawn from the study for bronchodilator administration who were then transferred to the PICU), or Respiratory Distress Assessment Instrument (RDAI) increase of 4 or more points within 30 minutes of a study treatment</description>
          <population>all patients enrolled in the study were analyzed for events related to clinical worsening</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Adverse Events</title>
        <description>Clinical worsening events (defined prior) + 7 day readmissions</description>
        <time_frame>Time of enrollment in the study through 1 week after hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Total Adverse Events</title>
          <description>Clinical worsening events (defined prior) + 7 day readmissions</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>LOS in Subgroup of Patients With Testing Positive for Respiratory Syncitial Virus (RSV+)</title>
        <time_frame>through hospitalization/while receiving study medication, average 2-3 days</time_frame>
        <population>This is the population in the study whose RSV testing was positive.</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>LOS in Subgroup of Patients With Testing Positive for Respiratory Syncitial Virus (RSV+)</title>
          <population>This is the population in the study whose RSV testing was positive.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.6" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>LOS in Patients With a History of Previous Wheeze</title>
        <time_frame>through hospitalization/while receiving study medication, average 2-3 days</time_frame>
        <population>Subgroup of the study population who reported a history of wheezing prior to this admission</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>LOS in Patients With a History of Previous Wheeze</title>
          <population>Subgroup of the study population who reported a history of wheezing prior to this admission</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.1" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>LOS Subgroup Analysis of Patients With a History of Prematurity</title>
        <time_frame>through hospitalization/while receiving study medication, average 2-3 days</time_frame>
        <population>Patients who reported a history of prematurity/whose Gestational age was &lt;37 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>LOS Subgroup Analysis of Patients With a History of Prematurity</title>
          <population>Patients who reported a history of prematurity/whose Gestational age was &lt;37 weeks</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>LOS Analysis for Patients Whose Study Entry Respiratory Distress Assessment Instrument (RDAI) Was Greater Than or Equal to 4 or Who Had Hypoxia &lt;92%</title>
        <time_frame>through hospitalization/while receiving study medication, average 2-3 days</time_frame>
        <population>Subgroup of patients who had a study entry Respiratory Distress Assessment Instrument (RDAI) of greater than or equal to 4 points OR hypoxia &lt;92% on admission</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>LOS Analysis for Patients Whose Study Entry Respiratory Distress Assessment Instrument (RDAI) Was Greater Than or Equal to 4 or Who Had Hypoxia &lt;92%</title>
          <population>Subgroup of patients who had a study entry Respiratory Distress Assessment Instrument (RDAI) of greater than or equal to 4 points OR hypoxia &lt;92% on admission</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.3" upper_limit="4.1"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.3" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay in the Study-LOS by Per Protocol Analysis</title>
        <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
        <time_frame>Time of first study treatment until time of discharge</time_frame>
        <population>Per protocol analysis (only includes participants who completed the study)</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline</title>
            <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>4 mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in the Study-LOS by Per Protocol Analysis</title>
          <description>Length of stay will be defined by the duration between the time of first study treatment to the time a discharge order is placed. Alternatively, if a patient remains inpatient for other, non-bronchiolitis related reasons (i.e. social reasons, etc.) the time a patient could be discharged from the standpoint of bronchiolitis as documented by the attending, will be used.</description>
          <population>Per protocol analysis (only includes participants who completed the study)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.2" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypertonic Saline</title>
          <description>4 mL nebulized 3% sodium chloride every 4 hours until discharge</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>4mL nebulized 0.9% sodium chloride every 4 hours until discharge</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Readmission-non-respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Transfer to PICU</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Readmission-respiratory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alyssa Silver</name_or_title>
      <organization>Children's Hospital at Montefiore/Albert Einstein College of Medicine</organization>
      <phone>718-741-2304</phone>
      <email>alysilve@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

